test
Search publications, data, projects and authors

Article

English

ID: <

oai:doaj.org/article:9edcc3a1a2d949028895fbac6192b56f

>

Where these data come from
Interleukin 2 as a potential cancer marker in patients after kidney transplantation

Abstract

Introduction. Transplant recipients have a significantly greater incidence of cancer, compared with the general population, who are referred to immunosuppressive therapy as an additional malignancy risk factor. Therefore, there is a need to search for an easy in clinical practice neoplasm predictor, especially for this group of patients. Materials and methods. A group of 74 (43M and 31F; aged 46.8 ± 12 years) kidney transplant recipients was investigated in a three-year follow-up study. During the time of observation, 7 patients were diagnosed with neoplasm (7.4 ± 1.5 years after transplantation). A serum level of IL2 (ELISA test) and mRNA level of IL1beta, IL10 and TNFalfa in peripheral mononuclear blood cells – PBMCs (QRT – PCR method) were measured in every year of observation. [i]Analysis of variances and t-Student test were used in groups mean comparison[/i]: N – patients developing malignant neoplasm group (24 probes); M – set of probes from patients with malignancies at the moment of diagnosis (11 probes); P – set of probes from patients before developing malignant neoplasm (10 probes); C – control group of healthy transplant recipients (31 probes). Results. Among the analyzed agents, only serum IL2 level differed between the analyzed groups, with higher values in the M compared with the P group (p<0.05) and with C group (p<0.01). There were no differences neither between N and C or P and C groups (p = 0.98), nor any correlation between IL2 and IL1b, IL2 and TNFalfa. Conclusions. The results may indicate that IL2 serum level might be consider as a useful late unspecific cancer marker, although larger studies should yield verification of this finding.

Your Feedback

Please give us your feedback and help us make GoTriple better.
Fill in our satisfaction questionnaire and tell us what you like about GoTriple!